# Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Source: https://onco.cc/trials/nct00376883/  
OnCo record `nct00376883` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.

## Summary

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month is a phase 3 interventional study registered as NCT00376883 by Nordic Myeloma Study Group, with 500 participants recorded, started 2000-01. Interventions recorded: pamidronate. Conditions recorded: Multiple Myeloma.

Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00376883
- Phase: 3
- Setting: The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.
- Sponsor: Nordic Myeloma Study Group
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT00376883: https://clinicaltrials.gov/study/NCT00376883

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Pamidronate](https://onco.cc/drugs/pamidronate/)

---
JSON: https://onco.cc/api/v1/entities/nct00376883.json